View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Dashboards
  2. Surveys
April 1, 2021

Nearly half of other service providers started using decentralised trials before pandemic

Decentralised trials (DCTs) or virtual trials are those that allow patients to participate in the studies without visiting the clinic site.

Decentralised trials (DCTs) or virtual trials are those that allow patients to participate in the studies without visiting the clinic site.

The use of DCTs soared following the COVID-19 pandemic after lockdowns were imposed and several restrictions were placed on movement.

GlobalData conducted a survey to assess pre-pandemic DCT use by company role.

Nearly half of other service providers started using DCTs before pandemicPre-pandemic Decentralised Trial Use by Company Role

The survey found that nearly half (49%) of other contract service providers started using DCTs before the COVID-19 pandemic. It includes CMOs, bioanalysis, training, consulting, software and digital solution providers for clinical trials.

The adoption rate of virtual trials before coronavirus stood at 42% and 36% for CROs and clinical/ investigator sites, respectively.

The survey also found that only 19% of Pharma/ Biotech and 14% of Government/ Academic Institutes explored DCTs before the pandemic hit the world.

The analysis is based on responses received from the GlobalData Coronavirus Survey -– Pharmaceutical Imports/Exports and Supply Chain,​ fielded between 04 June and 22 June 2020.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology